Free Trial
NASDAQ:IMNM

Immunome (IMNM) Stock Price, News & Analysis

Immunome logo
$6.24 -0.47 (-7.00%)
Closing price 04:00 PM Eastern
Extended Trading
$6.27 +0.03 (+0.48%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Immunome Stock (NASDAQ:IMNM)

Key Stats

Today's Range
$6.08
$6.55
50-Day Range
$6.24
$11.83
52-Week Range
$6.09
$22.03
Volume
1.12 million shs
Average Volume
880,329 shs
Market Capitalization
$542.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.14
Consensus Rating
Buy

Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Remove Ads

Immunome Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

IMNM MarketRank™: 

Immunome scored higher than 54% of companies evaluated by MarketBeat, and ranked 462nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immunome has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Immunome's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunome are expected to decrease in the coming year, from ($2.21) to ($3.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunome is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunome is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunome has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Immunome's valuation and earnings.
  • Percentage of Shares Shorted

    12.59% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 9.8.
  • Change versus previous month

    Short interest in Immunome has recently increased by 2.37%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Immunome does not currently pay a dividend.

  • Dividend Growth

    Immunome does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.59% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 9.8.
  • Change versus previous month

    Short interest in Immunome has recently increased by 2.37%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Immunome has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Immunome this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for IMNM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    29 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is an increase of 222% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,322,995.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 8.60% of the stock of Immunome is held by insiders.

  • Percentage Held by Institutions

    44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunome's insider trading history.
Receive IMNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.

IMNM Stock News Headlines

Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
Clay Siegall Bought 20% More Shares In Immunome
Immunome CEO buys $999.5K in common stock
See More Headlines

IMNM Stock Analysis - Frequently Asked Questions

Immunome's stock was trading at $10.62 at the start of the year. Since then, IMNM stock has decreased by 41.2% and is now trading at $6.24.
View the best growth stocks for 2025 here
.

Immunome, Inc. (NASDAQ:IMNM) posted its quarterly earnings data on Wednesday, March, 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.16. The business earned $2.74 million during the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative trailing twelve-month return on equity of 48.63%.

Immunome (IMNM) raised $30 million in an IPO on Friday, October 2nd 2020. The company issued 2,500,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO.

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
3/19/2025
Today
4/03/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMNM
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.14
High Stock Price Target
$33.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+302.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-106,810,000.00
Net Margins
-3,014.59%
Pretax Margin
-3,014.59%

Debt

Sales & Book Value

Annual Sales
$9.04 million
Price / Cash Flow
N/A
Book Value
$2.77 per share
Price / Book
2.25

Miscellaneous

Free Float
72,916,000
Market Cap
$542.57 million
Optionable
Optionable
Beta
1.93
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:IMNM) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners